EPAS1 and von Hippel-Lindau disease: The most promising molecule under investigation is belzutifan (MK-6482, previously called PT2977), an HIF-2α inhibitor that showed activity in patients with RCC and non–RCC neoplasms associated with VHL diseases [20], and a phase 3 trial is planned.